Low-dose naltrexone (LDN) is not addictive. It has no potential for physical dependence, produces no withdrawal symptoms when stopped, and is not classified as a controlled substance. In fact, naltrexone is the pharmacological opposite of an addictive drug: it blocks the same receptors that opioids activate, meaning it cannot produce a “high” or trigger the reward pathways that drive addiction.
Why LDN Cannot Produce Addiction
Drugs become addictive when they flood the brain’s reward system with feel-good signaling, creating a cycle of craving and escalating use. Naltrexone does the reverse. It is a potent blocker of the brain’s primary opioid receptors, the same receptors targeted by morphine, heroin, and prescription painkillers. At full doses (50 mg), naltrexone actually reduces the brain’s baseline reward signaling over time. This is why full-dose naltrexone is FDA-approved to help people recover from opioid and alcohol addiction: it makes those substances less rewarding.
LDN uses a much smaller dose, typically between 1 and 4.5 mg. At this low dose, the receptor blockade is brief rather than sustained. After the drug wears off, the body responds by temporarily ramping up its own natural endorphin production and becoming more sensitive to those endorphins. This “rebound” effect is the proposed mechanism behind LDN’s benefits for pain and inflammation. But even this upregulation of the body’s own opioid system does not create dependence, because the process works through the body’s natural chemistry rather than flooding it with an external substance.
No Withdrawal When You Stop
Clinical researchers studying LDN for chronic pain have directly addressed this question: no withdrawal symptoms have been observed when LDN treatment is stopped, and withdrawal is not a known effect of discontinuation. Unlike many other medications used for chronic conditions (certain antidepressants, sleep aids, or anti-anxiety drugs), LDN does not require tapering. You can simply stop taking it.
The LDN Research Trust confirms this in its guidance, noting that patients should not experience withdrawal symptoms when discontinuing LDN and that there is no need to taper the dose down. The one exception involves people who are also taking opioid medications. If someone starts LDN without first tapering off opioids, the naltrexone can rapidly displace the opioid from its receptors and trigger a sudden, intense wave of withdrawal symptoms. This is called precipitated withdrawal, and it is a reaction to the opioid leaving the receptors abruptly, not a sign that LDN itself is habit-forming.
What Happens After Stopping LDN
Some people worry that the symptoms LDN was managing (pain, fatigue, inflammation) will come roaring back worse than before. This is a reasonable concern, since some medications cause a “rebound” worsening of the original condition. With LDN, the clinical evidence does not support this. When you stop, the benefits of the drug gradually fade as the temporary boost to your endorphin system normalizes. Your underlying condition may return to its pre-treatment state, but it should not become worse than it was before you started.
This is an important distinction. Feeling your original symptoms return is not the same as withdrawal. It simply means the medication was helping, and now it isn’t there anymore.
LDN’s Regulatory Classification
The U.S. Drug Enforcement Administration removed naltrexone from all controlled substance schedules in 1975, finding that it has an accepted medical use and does not have a potential for abuse to justify control under the Controlled Substances Act. It sits in the same regulatory category as drugs like blood pressure medications or antibiotics, not alongside substances with abuse potential. No prescriber needs a special license to prescribe it, and no pharmacy treats it as a controlled drug.
Side Effects That Do Occur
LDN is not addictive, but it is not side-effect-free. A meta-analysis of randomized controlled trials in fibromyalgia patients found two side effects that occurred more often with LDN than with placebo: vivid dreams (about three times more likely) and nausea (roughly 2.75 times more likely). Neither is dangerous, but both can be bothersome, especially in the first weeks of treatment.
Other commonly reported effects like headache, diarrhea, and dizziness showed no statistically significant difference from placebo in pooled trial data. Serious adverse events were also no more common in LDN groups than in placebo groups. Most people who experience side effects find they diminish after the first few weeks, which is why prescribers often recommend starting at a lower dose (around 1 mg) and gradually increasing to the target dose of 3 to 4.5 mg.
How LDN Differs From Full-Dose Naltrexone
Full-dose naltrexone (50 mg daily or a monthly injection) is prescribed specifically to treat opioid and alcohol addiction. At that dose, it creates a sustained, near-complete blockade of opioid receptors. This means if someone drinks alcohol or uses opioids while on it, they feel little or no reward. Full-dose naltrexone is also not addictive, but it works through a different intensity of receptor blockade and is used for a completely different purpose.
LDN, at roughly one-tenth the addiction-treatment dose, creates only a brief blockade lasting a few hours. The therapeutic goal is not to block reward signaling but to nudge the body into producing more of its own endorphins and related growth factors. The two uses share a molecule but differ in dose, duration of action, and intended effect. Neither version carries addiction risk.